All In Biotech

Drug Trial Radar · NCT00376194

Mercury Chelation to Treat Autism

An Investigation of the Efficacy of Mercury Chelation as a Treatment for Autism Spectrum Disorder

Last checked: Nov 20, 2026Latest source record: Sep 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Sep 2006

Primary completion

Not stated

Study completion Mar 2007

Sponsor

Sponsor type
NIH
First posted
Sep 14, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine whether DMSA, an oral chelating agent that removes mercury and other metals from the body, is beneficial for children with autism. DMSA is commonly used to treat autism, although it has never been tested in a controlled study and there is no proof that it helps children with the disorder. Support for its use is based on single-case reports of benefits of chelation with DMSA. This study will help determine whether or not DMSA is useful for treating autism. Children between 4 and 10 years of age with autism spectrum disorder who weigh at least 33 pounds, who have detectable, but not toxic, levels of mercury or lead in the blood, and who have not previously received chelation therapy may be eligible for this study. Participants complete a medical history, behavioral and psychological assessment and physical examination. Blood, hair, urine and stool samples are collected for testing. Because DMSA can remove minerals the body needs, such as zinc and iron, as well as the toxic lead and mercury, participants take a daily multivitamin supplement starting 1 month before beginning chelation therapy and continuing for the duration of treatment. After 1 month of the supplementation regimen, the children are assigned to receive DMSA or placebo for 12 weeks, divided into six 2-week cycles. They take the assigned drug 3 times a day on days 1, 2 and 3 of each cycle and continue the multivitamin every day. The children are seen in the clinic immediately before and after the first, third and sixth cycles. At each checkup, the parent or guardian answers a set of questions about the child's autism symptoms, physical health and medication side effects. Blood, urine and stool samples are collected for laboratory testing. ...

Conditions

  • Autism
  • Asperger's Disorder
  • Child Development Disorders, Pervasive

Interventions

  • DMSADrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in social reciprocity.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Mental Health (NIMH), 9000 Rockville Pike

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.